Age alone is not a contraindication to biologic therapy in psoriasis — yet elderly patients remain systematically undertreated because of persistent safety myths, according to a new analysis published by Dermatology Times.

The report addresses a long-standing tension in psoriasis management: biologic therapies have transformed outcomes for moderate-to-severe disease, but prescribers frequently hesitate to offer them to patients in older age groups. The piece, titled "Debunking Biologic Safety Myths in Elderly Psoriasis Patients," examines the evidence gap between perceived and documented risk in this cohort.

Why do prescribers hesitate in older patients?

The hesitation stems from several recurring concerns that the analysis sets out to challenge. Clinicians often worry that elderly patients face heightened infection risk on immunomodulatory therapy, that comorbidities and polypharmacy make biologics too complicated, and that trial data simply does not apply to older adults.

These concerns have real consequences. When biologics are withheld, elderly psoriasis patients are frequently left on systemic agents such as methotrexate or cyclosporine, or on chronic topical corticosteroids — options that carry their own, often underappreciated, safety burdens in this population.

What does the evidence actually show?

The Dermatology Times analysis argues that the mythology around biologic risk in older patients outpaces the documented signal. The piece frames biologic safety in the elderly as an area where assumption has outrun data, and it encourages clinicians to weigh the risk of biologics against the risk of the alternatives — including untreated or undertreated disease itself.

Psoriasis in older patients is not a benign condition. Chronic systemic inflammation, impaired quality of life, and the cumulative toxicity of conventional therapies all factor into the risk-benefit calculus that the report asks prescribers to apply.

A shifting risk-benefit conversation

For dermatologists, the practical takeaway is to interrogate the source of each safety concern before it drives prescribing behavior. Where fear of infection, malignancy, or treatment complexity is grounded in trial data or pharmacovigilance, it deserves weight. Where it reflects habit or extrapolation from other drug classes, the report suggests it should not stand between an elderly patient and effective clearance.

The analysis also implicitly raises a research question: as the psoriasis population ages, real-world evidence specific to older biologic users becomes increasingly valuable for confirming the safety profile that clinicians are asked to trust.

As demographic trends push more psoriasis patients into older age brackets, expect the field to keep refining — and increasingly defending — the case for biologics in the elderly.